Expand OVID Menu
OVID MENU

OVID Latest Headlines

Guggenheim Keeps Their Buy Rating on Ovid Therapeutics (OVID)

at www.tipranks.com (Mon, 16-Nov 8:17 AM)

Market Data Delayed 15 Minutes